Academia
Model :
PYC can be said to belong in a group of sciences categorised under the Naturalist label. Primarily as it's library of peptides are not synthesized by us but have evolved and adapted own their own as entities to stand the test of time thus far.
Within the scientific domain, a hypothesis suggested by the Naturalist, based on the big bang theory, is all Matter originated from one source.
One of the objectives of PYC is to qualify their library of these animo acids to the hypothesis.
Why the need?
Currently, the scientific community predict an array of resistances in areas such as superbug, supervirul ect.
The cause and effect of this prediction is simply evolution and adaptability to current medicine, hence resistance.
Peptides, sure as those PYC is currently testing, have as already stated, as an entity survived, adapted, and evolved over millions of years.
PYC Scientific
Model:
The monotherapy data, although at an early stage, is encouraging (operations update).
The cargo element is of further interest. The ability to penetrate the cell membrane and release a drug makes PYC's science attractive to combined therapies.
This we are seeing with collaborations currently and no dought in future to come.
For example, one or more of the 5 FDAs as well as the extended Genetech decision.
In synergy, a company combining it's drug utilising a vehicle provided by PYC as a combined therapy will look at the data and most recently released (operations update) it's toxicity levels.
As this component currently suggestive of low to insignificant even on dosages above normal administration levels, then this is certainly not only a need but a want as well.
Why?
For one, it allows a combined drug company to collaborate in a combined therapy one a larger dosage of their own (potency escalation).
Two, the company data of it's own toxicity levels may not have a crossover effect when combined with a vehicle with non significant toxicity levels.
So, theoretically, a higher efficacy in data results.
The business model is not discussed here, as is of topic on the other current threads.
Cheers psych
- Forums
- ASX - By Stock
- PYC
- Last Sunday reading
PYC
pyc therapeutics limited
Add to My Watchlist
1.56%
!
$1.27

Last Sunday reading
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.27 |
Change
-0.020(1.56%) |
Mkt cap ! $737.8M |
Open | High | Low | Value | Volume |
$1.29 | $1.29 | $1.25 | $4.616M | 3.649M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 19940 | $1.25 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.27 | 1008 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 19940 | 1.250 |
2 | 4225 | 1.225 |
1 | 20000 | 1.220 |
1 | 4000 | 1.200 |
1 | 8000 | 1.135 |
Price($) | Vol. | No. |
---|---|---|
1.265 | 1008 | 1 |
1.270 | 6262 | 1 |
1.285 | 58876 | 2 |
1.295 | 24500 | 1 |
1.300 | 28670 | 3 |
Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
3DA
AMAERO LTD
Hank Holland, Chairman & CEO
Hank Holland
Chairman & CEO
Previous Video
Next Video
SPONSORED BY The Market Online